Last $11.26 USD
Change Today +0.14 / 1.26%
Volume 131.6K
LJPC On Other Exchanges
As of 12:28 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

la jolla pharmaceutical co (LJPC) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/11/14 - $19.50
52 Week Low
07/26/13 - $2.78
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

la jolla pharmaceutical co (LJPC) Related Bloomberg News

View More Bloomberg News

la jolla pharmaceutical co (LJPC) Related Businessweek News

No Related Businessweek News Found

la jolla pharmaceutical co (LJPC) Details

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for chronic organ failure and cancer. The company’s products include GCS-100 that is in Phase II clinical trial for the treatment of chronic kidney disease. It also provides LJPC-501, a peptide agonist of the renin-angiotensin system, which is designed to help restore kidney function in patients with hepatorenal syndrome; and LJPC-401, a peptide for the treatment of iron disorders. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.

7 Employees
Last Reported Date: 03/31/14
Founded in 1989

la jolla pharmaceutical co (LJPC) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $420.0K
Compensation as of Fiscal Year 2013.

la jolla pharmaceutical co (LJPC) Key Developments

LJPC Seeks Acquisitions

La Jolla Pharmaceutical Co. (NasdaqCM:LJPC) is looking for acquisition opportunities. LJPC intends to use the net proceeds from the underwritten offering for general corporate purposes, funding its ongoing and future clinical trials, general and administrative expenses and potential future acquisitions and other strategic purposes.

La Jolla Pharmaceutical Company Announces Positive Pre-Clinical Data for Oral Galectin-3 Inhibitor in Nonalcoholic Steatohepatitis (NASH)

La Jolla Pharmaceutical Company announced positive pre-clinical data for LJPC-1010 in non-alcoholic steatohepatitis (NASH). LJPC-1010 is a derivative of GCS-100, a carbohydrate inhibitor of galectin-3, which has shown activity in chronic kidney disease in a phase 2 trial. In a pre-clinical study of liver fibrosis in the STAM model of NASH, LJPC-1010 showed a significant reduction (p<0.001) vs control vehicle in nonalcoholic fatty liver disease (NAFLD) activity score, a system of scoring the features of NAFLD. Importantly, LJPC-1010 had a significant impact on all three measures used to derive the NAFLD score, namely steatosis, lobular inflammation and hepatocyte ballooning indicating broad effects. In addition to NAFLD, animals in the LJPC-1010 group had decreased yellowing of the liver, decreased liver weight and decreased fibrosis compared to the control group. Like GCS-100, LJPC-1010 is a modified pectin, however, LJPC-1010, at 50 mg/kg showed significant activity in NASH compared to GCS-100 at 300 mg/kg (both given orally) which showed a trend toward improvement but did reach statistical significance. LJPC-1010 given orally was comparable to an equivalent dose of GCS-100 given intravenously. The company intends to file an Investigational New Drug application and initiate a phase 1/2 clinical trial in NASH in the first half of 2015.

La Jolla Pharmaceutical Co. - Special Call

To discuss the plans to begin a phase 3 registration program for LJPC-501 for the treatment of catecholamine-resistant hypotension


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LJPC:US $11.26 USD +0.14

LJPC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LJPC.
View Industry Companies

Industry Analysis


Industry Average

Valuation LJPC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LA JOLLA PHARMACEUTICAL CO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at